Cargando…

Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2‐Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

BACKGROUND: The observational study HerMES collected primary data on effectiveness and safety of trastuzumab in patients with human epidermal growth receptor 2 (HER2)‐positive cancer of the stomach or gastroesophageal junction (GEJ) in routine clinical practice, exploring the treatment with trastuzu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al‐Batran, Salah‐Eddin, Moorahrend, Enno, Maintz, Christoph, Goetze, Thorsten O., Hempel, Dirk, Thuss‐Patience, Peter, Gaillard, Vincent E., Hegewisch‐Becker, Susanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Gastrointestinal Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418356/ https://www.ncbi.nlm.nih.gov/pubmed/32311799 http://dx.doi.org/10.1634/theoncologist.2020-0109

Ejemplares similares

Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
por: Catenacci, Daniel V., et al.
Publicado: (2021)

Multimodal Treatment Strategies in Esophagogastric Junction Cancer: a Western Perspective
por: Goetze, Thorsten Oliver, et al.
Publicado: (2019)

Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma
por: Anderegg, M. C. J., et al.
Publicado: (2017)

Perspectives on the Management of Oligometastatic Disease in Esophago-Gastric Cancer
por: Goetze, Thorsten Oliver, et al.
Publicado: (2022)

Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma
por: Jiang, Man, et al.
Publicado: (2022)

Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)
por: Tintelnot, Joseph, et al.
Publicado: (2020)

Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status
por: Wood, Anthony C, et al.
Publicado: (2022)

Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415)
por: Lorenzen, Sylvie, et al.
Publicado: (2023)

Swallowing MRI—a reliable method for the evaluation of the postoperative gastroesophageal situs after Nissen fundoplication
por: Arnoldner, Michael A., et al.
Publicado: (2018)

Leiomyosarcoma of the rectosigmoid junction, a case report
por: Avendano, Tania Lisseth Mercado, et al.
Publicado: (2020)

Treatment for metastatic adenocarcinoma of the stomach and gastroesophageal junction: 2020
por: Hsu, Andrew, et al.
Publicado: (2020)

Targeting Gastric Cancer with Trastuzumab: New Clinical Practice and Innovative Developments to Overcome Resistance
por: Roukos, Dimitrios H.
Publicado: (2009)

Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
por: Moehler, Markus, et al.
Publicado: (2016)

FGFR2‐Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape
por: Klempner, Samuel J., et al.
Publicado: (2019)

Initial Report of Second‐Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi‐Institutional Retrospective Analysis
por: Klempner, Samuel J., et al.
Publicado: (2018)

The association between diabetes and gastric cancer: results from the Stomach Cancer Pooling Project Consortium
por: Dabo, Bashir, et al.
Publicado: (2021)

Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer
por: Lordick, Florian, et al.
Publicado: (2023)

Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States
por: Sharma, Prateek, et al.
Publicado: (2023)

The Role of Three-Dimensional Multidetector CT Gastrography in the Preoperative Imaging of Stomach Cancer: Emphasis on Detection and Localization of the Tumor
por: Kim, Jin Woong, et al.
Publicado: (2015)

Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer: A Retrospective Analysis
por: Park, Joo-Hwan, et al.
Publicado: (2022)

RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV
por: Lorenzen, Sylvie, et al.
Publicado: (2020)

Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data
por: Janowitz, Tobias, et al.
Publicado: (2016)

Radiotherapy for tumors of the stomach and gastroesophageal junction – a review of its role in multimodal therapy
por: Buergy, Daniel, et al.
Publicado: (2012)

Human Epidermal Growth Factor Receptor 2 Expression in Unresectable Gastric Cancers: Relationship with CT Characteristics
por: Lee, Jeong Sub, et al.
Publicado: (2017)

Sarcopenia as a prognostic factor for survival in patients with locally advanced gastroesophageal adenocarcinoma
por: Koch, Christine, et al.
Publicado: (2019)

The New American Joint Committee on Cancer/International Union Against Cancer Staging System for Adenocarcinoma of the Stomach: Increased Complexity without Clear Improvement in Predictive Accuracy
por: Dikken, Johan L., et al.
Publicado: (2012)

Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma
por: Lordick, Florian, et al.
Publicado: (2021)

Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma – the phase III “PREVENT”- (FLOT9) trial of the AIO /CAOGI /ACO
por: Götze, Thorsten O., et al.
Publicado: (2021)

Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction
por: Mingol, Fernando, et al.
Publicado: (2015)

Frequency of Positive Familial Criteria in Patients with Adenocarcinoma of the Esophageal-Gastric Junction and Stomach: First Prospective Data in a Caucasian Cohort †
por: Schölzchen, Jan, et al.
Publicado: (2022)

The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer
por: Atmaca, Akin, et al.
Publicado: (2012)

Postoperative Chemoradiotherapy Combined with Epirubicin-Based Triplet Chemotherapy for Locally Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction
por: Li, Guichao, et al.
Publicado: (2013)

Withholding the Introduction of Anti‐Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild‐Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study)
por: Palmieri, Lola‐Jade, et al.
Publicado: (2019)

Impact of Postoperative Chemotherapy in Patients with Gastric/Gastroesophageal Adenocarcinoma Treated with Perioperative Chemotherapy
por: Ballhausen, Alexej, et al.
Publicado: (2022)

Local staging of rectal cancer: the current role of MRI
por: Klessen, Christian, et al.
Publicado: (2006)

New coil concept for endoluminal MR imaging: Initial results in staging of gastric carcinoma in correlation with Histopathology
por: Heye, Tobias, et al.
Publicado: (2006)

Better Survival in Patients with Esophageal Cancer After Surgical Treatment in University Hospitals: A Plea for Performance by Surgical Oncologists
por: Verhoef, Christian, et al.
Publicado: (2007)

Feasibility study of computed tomography colonography using limited bowel preparation at normal and low-dose levels study
por: Florie, Jasper, et al.
Publicado: (2007)

CT colonography: optimisation, diagnostic performance and patient acceptability of reduced-laxative regimens using barium-based faecal tagging
por: Taylor, Stuart A., et al.
Publicado: (2007)

Diagnostic value of CT-colonography as compared to colonoscopy in an asymptomatic screening population: a meta-analysis
por: de Haan, Margriet C., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_19rmrrgd31tr5f69hk13m2mfb6